Stockreport
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer [Yahoo! Finance]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine's financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. “We are delighted to welcome Svetlana to Prime Medicine,” said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. “Svetlana brings proven leadership at clinical-stage biotechnology companies, as well as deep capital markets expertise. As we prepare to enter the clinic in both Wilson Disease and Alpha-1 Antitrypsin Deficiency, her leadership will be instrumental in ensuring Prime Medicine is well positioned - both financially and strategically - to execute on the tremendous promise of Prime Editing for patients with Wilson Disease, AATD and beyond.” Ms. Makhni brings over 20 years of experience across multiple biotechnology and healthc
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance][Yahoo! Finance]
- Jim Cramer on Gilead Sciences: “I'd Hold On to It” [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences (GILD) had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer[Business Wire]
- Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- GILD's page on the SEC website
- More